Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Alzheimer’s Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Market Overview:

The global alzheimer’s drugs market reached a value of US$ 6.34 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 6.50% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Alzheimer's is a disease characterized by the degeneration of nerve cells in several areas of the brain. It causes loss of cognitive function, such as memory, language, thinking and behavior. The common symptoms of Alzheimer's include depression, memory impairment, loss of inhibitions, and problems with thinking and reasoning. It is usually diagnosed by performing physical exams, blood tests, brain imaging, and mental status and neuropsychological testing. According to the results, doctors prescribe different medications to alleviate symptoms. Alzheimer’s drugs influence the functions of neurotransmitters, the chemicals involved in carrying messages between nerve cells in the brain.

Alzheimer’s Drugs Market Trends:

Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy dietary patterns and smoking, are some of the factors known to increase the chances of developing Alzheimer's disease. An increase in the prevalence of these ailments and lifestyle choices among the masses, coupled with the rising geriatric population, represents one of the key factors driving the market growth. Furthermore, the leading pharmaceutical companies are focusing on the development of drugs that prevent the disease and provide long-lasting improvements in cognitive functions. The market growth is further supported by the expansion of telehealth services and the growing traction of online pharmacies. These platforms have enabled disease diagnosis and drug delivery in remote regions. Apart from this, various Alzheimer's drugs are presently under late-stage clinical trials, including Aducanumab, Solanezumab and Insulin. The development of these drugs is anticipated to propel the market growth in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global alzheimer’s drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

  • Donepezil
  • Galantamine
  • Rivastigmine
  • Memantine
  • Others
     

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores
  • Others
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited.

Report Coverage:

Report Features Details
Base Year of the Analysis 2020
Historical Period 2015-2020
Forecast Period 2021-2026
Units US$ Billion
Segment Coverage Drug Class, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Key Questions Answered in This Report:

  • How has the global alzheimer’s drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global alzheimer’s drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global alzheimer’s drugs market and who are the key players?
  • What is the degree of competition in the industry?

1    Preface
2    Scope and Methodology 

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Alzheimer’s Drugs Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Drug Class
    6.1    Donepezil
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Galantamine
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Rivastigmine
        6.3.1 Market Trends
        6.3.2 Market Forecast
    6.4    Memantine
        6.4.1 Market Trends
        6.4.2 Market Forecast
    6.5    Others
        6.5.1 Market Trends
        6.5.2 Market Forecast
7    Market Breakup by Distribution Channel
    7.1    Hospital Pharmacy
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Retail Pharmacy
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Online Stores
        7.3.1 Market Trends
        7.3.2 Market Forecast
    7.4    Others
        7.4.1 Market Trends
        7.4.2 Market Forecast
8    Market Breakup by Region
    8.1    North America
        8.1.1 United States
           8.1.1.1 Market Trends
           8.1.1.2 Market Forecast
        8.1.2 Canada
           8.1.2.1 Market Trends
           8.1.2.2 Market Forecast
    8.2    Asia Pacific
        8.2.1 China
           8.2.1.1 Market Trends
           8.2.1.2 Market Forecast
        8.2.2 Japan
           8.2.2.1 Market Trends
           8.2.2.2 Market Forecast
        8.2.3 India
           8.2.3.1 Market Trends
           8.2.3.2 Market Forecast
        8.2.4 South Korea
           8.2.4.1 Market Trends
           8.2.4.2 Market Forecast
        8.2.5 Australia
           8.2.5.1 Market Trends
           8.2.5.2 Market Forecast
        8.2.6 Indonesia
           8.2.6.1 Market Trends
           8.2.6.2 Market Forecast
        8.2.7 Others
           8.2.7.1 Market Trends
           8.2.7.2 Market Forecast
    8.3    Europe
        8.3.1 Germany
           8.3.1.1 Market Trends
           8.3.1.2 Market Forecast
        8.3.2 France
           8.3.2.1 Market Trends
           8.3.2.2 Market Forecast
        8.3.3 United Kingdom
           8.3.3.1 Market Trends
           8.3.3.2 Market Forecast
        8.3.4 Italy
           8.3.4.1 Market Trends
           8.3.4.2 Market Forecast
        8.3.5 Spain
           8.3.5.1 Market Trends
           8.3.5.2 Market Forecast
        8.3.6 Russia
           8.3.6.1 Market Trends
           8.3.6.2 Market Forecast
        8.3.7 Others
           8.3.7.1 Market Trends
           8.3.7.2 Market Forecast
    8.4    Latin America
        8.4.1 Brazil
           8.4.1.1 Market Trends
           8.4.1.2 Market Forecast
        8.4.2 Mexico
           8.4.2.1 Market Trends
           8.4.2.2 Market Forecast
        8.4.3 Others
           8.4.3.1 Market Trends
           8.4.3.2 Market Forecast
    8.5    Middle East and Africa
        8.5.1 Market Trends
        8.5.2 Market Breakup by Country
        8.5.3 Market Forecast
9    SWOT Analysis
    9.1    Overview
    9.2    Strengths
    9.3    Weaknesses
    9.4    Opportunities
    9.5    Threats
10    Value Chain Analysis
11    Porters Five Forces Analysis

    11.1    Overview
    11.2    Bargaining Power of Buyers
    11.3    Bargaining Power of Suppliers
    11.4    Degree of Competition
    11.5    Threat of New Entrants
    11.6    Threat of Substitutes
12    Price Analysis
13    Competitive Landscape

    13.1    Market Structure
    13.2    Key Players
    13.3    Profiles of Key Players
        13.3.1    Abbvie Inc.
           13.3.1.1 Company Overview
           13.3.1.2 Product Portfolio 
           13.3.1.3 Financials
           13.3.1.4 SWOT Analysis
        13.3.2    AstraZeneca PLC
           13.3.2.1 Company Overview
           13.3.2.2 Product Portfolio
           13.3.2.3 Financials
           13.3.2.4 SWOT Analysis
        13.3.3    Biogen Inc.
           13.3.3.1 Company Overview
           13.3.3.2 Product Portfolio 
           13.3.3.3 Financials 
           13.3.3.4 SWOT Analysis
        13.3.4    Daiichi Sankyo Company Limited
           13.3.4.1 Company Overview
           13.3.4.2 Product Portfolio 
           13.3.4.3 Financials 
           13.3.4.4 SWOT Analysis
        13.3.5    Eisai Co. Ltd.
           13.3.5.1 Company Overview
           13.3.5.2 Product Portfolio
           13.3.5.3 Financials 
           13.3.5.4 SWOT Analysis 
        13.3.6    Eli Lilly and Company
           13.3.6.1 Company Overview
           13.3.6.2 Product Portfolio 
           13.3.6.3 Financials
           13.3.6.4 SWOT Analysis 
        13.3.7    H. Lundbeck A/S
           13.3.7.1 Company Overview
           13.3.7.2 Product Portfolio
           13.3.7.3 Financials 
           13.3.7.4 SWOT Analysis
        13.3.8    F. Hoffmann-La Roche AG
           13.3.8.1 Company Overview
           13.3.8.2 Product Portfolio 
           13.3.8.3 SWOT Analysis
        13.3.9    Merck & Co. Inc.
           13.3.9.1 Company Overview
           13.3.9.2 Product Portfolio
           13.3.9.3 Financials 
           13.3.9.4 SWOT Analysis
        13.3.10    Novartis AG
           13.3.10.1 Company Overview
           13.3.10.2 Product Portfolio 
           13.3.10.3 Financials
           13.3.10.4 SWOT Analysis
        13.3.11    Ono Pharmaceutical Co. Ltd.
           13.3.11.1 Company Overview
           13.3.11.2 Product Portfolio 
           13.3.11.3 Financials
           13.3.11.4 SWOT Analysis
        13.3.12    Pfizer Inc.
           13.3.12.1 Company Overview
           13.3.12.2 Product Portfolio 
           13.3.12.3 Financials
           13.3.12.4 SWOT Analysis
        13.3.13    Teva Pharmaceutical Industries Limited
           13.3.13.1 Company Overview
           13.3.13.2 Product Portfolio 
           13.3.13.3 Financials
           13.3.13.4 SWOT Analysis

List of Figures

Figure 1: Global: Alzheimer’s Drugs Market: Major Drivers and Challenges
Figure 2: Global: Alzheimer’s Drugs Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Alzheimer’s Drugs Market: Breakup by Drug Class (in %), 2020
Figure 4: Global: Alzheimer’s Drugs Market: Breakup by Distribution Channel (in %), 2020
Figure 5: Global: Alzheimer’s Drugs Market: Breakup by Region (in %), 2020
Figure 6: Global: Alzheimer’s Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 7: Global: Alzheimer’s Drugs (Donepezil) Market: Sales Value (in Million US$), 2015 & 2020
Figure 8: Global: Alzheimer’s Drugs (Donepezil) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 9: Global: Alzheimer’s Drugs (Galantamine) Market: Sales Value (in Million US$), 2015 & 2020
Figure 10: Global: Alzheimer’s Drugs (Galantamine) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 11: Global: Alzheimer’s Drugs (Rivastigmine) Market: Sales Value (in Million US$), 2015 & 2020
Figure 12: Global: Alzheimer’s Drugs (Rivastigmine) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 13: Global: Alzheimer’s Drugs (Memantine) Market: Sales Value (in Million US$), 2015 & 2020
Figure 14: Global: Alzheimer’s Drugs (Memantine) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 15: Global: Alzheimer’s Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2015 & 2020
Figure 16: Global: Alzheimer’s Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 17: Global: Alzheimer’s Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2015 & 2020
Figure 18: Global: Alzheimer’s Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 19: Global: Alzheimer’s Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2015 & 2020
Figure 20: Global: Alzheimer’s Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 21: Global: Alzheimer’s Drugs (Online Stores) Market: Sales Value (in Million US$), 2015 & 2020
Figure 22: Global: Alzheimer’s Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 23: Global: Alzheimer’s Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2015 & 2020
Figure 24: Global: Alzheimer’s Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 25: North America: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 26: North America: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 27: United States: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 28: United States: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 29: Canada: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 30: Canada: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 31: Asia Pacific: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 32: Asia Pacific: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 33: China: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 34: China: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 35: Japan: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 36: Japan: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 37: India: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 38: India: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 39: South Korea: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 40: South Korea: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 41: Australia: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 42: Australia: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 43: Indonesia: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 44: Indonesia: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 45: Others: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 46: Others: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 47: Europe: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 48: Europe: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 49: Germany: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 50: Germany: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 51: France: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 52: France: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 53: United Kingdom: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 54: United Kingdom: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 55: Italy: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 56: Italy: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 57: Spain: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 58: Spain: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 59: Russia: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 60: Russia: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 61: Others: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 62: Others: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 63: Latin America: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 64: Latin America: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 65: Brazil: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 66: Brazil: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 67: Mexico: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 68: Mexico: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 69: Others: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 70: Others: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 71: Middle East and Africa: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 72: Middle East and Africa: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 73: Global: Alzheimer’s Drugs Industry: SWOT Analysis
Figure 74: Global: Alzheimer’s Drugs Industry: Value Chain Analysis
Figure 75: Global: Alzheimer’s Drugs Industry: Porter’s Five Forces Analysis

List of Tables

Table 1: Global: Alzheimer’s Drugs Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Alzheimer’s Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2021-2026
Table 3: Global: Alzheimer’s Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
Table 4: Global: Alzheimer’s Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 5: Global: Alzheimer’s Drugs Market: Competitive Structure
Table 6: Global: Alzheimer’s Drugs Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2299

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links